** Shares of Roivant Sciences ROIV.O fall 2.2% to $12.20 before the bell
** Co says its experimental lung disease drug, namilumab, did not meet the main and secondary goals in a mid-stage study
** Co was testing namilumab in patients with chronic active pulmonary sarcoidosis, a condition in which lumps of inflammatory cells form in the lungs
** Adds that it will stop further development of the drug to treat sarcoidosis
** As of last close, ROIV up 11% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.